TY - JOUR
T1 - Targeting the lung using siRNA and antisense based oligonucleotides
AU - Moschos, Sterghios
AU - Spinks, Karen
AU - Williams, Andrew Evan
AU - Lindsay, Mark
PY - 2008
Y1 - 2008
N2 - The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.
AB - The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.
U2 - 10.2174/138161208786898851
DO - 10.2174/138161208786898851
M3 - Article
SN - 1381-6128
VL - 14
SP - 3620
EP - 3627
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 34
ER -
